Geoffrey Wu
Geoffrey Wu, PhD*, is a regulatory review officer, geoffrey.wu@fda.hhs.gov.
Articles
Regulatory Considerations for Controlled Correspondence Related to Generic Drug Chemistry
Geoffrey Wu;Lane Christensen;Thomas O’Connor;Frank Holcombe Jr.;Susan Rosencrance;Andre Raw;Kristina Adams;Xiaochuan Yang;Min Li
September 1st 2015An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: October 28th 2024 | Updated: November 25th 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 6th 2024 | Updated: November 25th 2024
Automate Aseptic Filling: Closing the System at Full Modularity
Published: November 5th 2024 | Updated: November 25th 2024
Untethered Data: Unifying and Contextualizing Drug Discovery Data
Published: November 8th 2024 | Updated: November 25th 2024
Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification
